Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148308 | 0.89 | EPHX2 (0.53) | LMNAPARP10EPHX2FAAH | |
| SCHEMBL12440598 | 0.86 | EPHX2 (0.42) | PARP10EPHX2FAAHACACB | |
| SCHEMBL17873483 | 0.83 | LMNA (0.61) | SMN1; SMN2LMNAPARP10POLBEPHX2 | |
| SCHEMBL14127724 | 0.82 | CYP19A1 (0.46) | EPHX2MAPTL3MBTL1 | |
| SCHEMBL14235504 | 0.82 | CYP19A1 (0.46) | EPHX2MAPTL3MBTL1 | |
| SCHEMBL10186118 | 0.81 | LMNA (0.48) | SMN1; SMN2LMNAEPHX2FAAHMAPT | |
| SCHEMBL13117542 | 0.81 | LMNA (0.51) | SMN1; SMN2LMNAPOLBEPHX2MAPT | |
| SCHEMBL10184281 | 0.80 | KDM4E (0.47) | SMN1; SMN2LMNAEPHX2FAAHMAPT | |
| SCHEMBL10185038 | 0.80 | KDM4E (0.47) | SMN1; SMN2LMNAEPHX2FAAHMAPT | |
| SCHEMBL15043518 | 0.80 | ALDH1A1 (0.48) | LMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | SMN1; SMN2 4464/4885LMNA 2889/4885PARP10 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.